Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

OCT 2 3 2006

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/563,566			
Filing Date	02/23/2006			
First Named Inventor	Brain A. Whittle			
Art Unit				
Examiner Name				
Attorney Docket Number	187287/US (466600-15)			

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2</sup> (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
/MC/	A1	<sup>US-</sup> 3,980,766	09-14-1976	Shaw et al.	
		US-			
		US-		The second secon	
		US-			
•		US-			
		US-			
		US-	<del></del>		
		US-			
		US			-
		US-			
		US-			
		US-	T		
		US-			
		US-		,	
		US-	<del></del>		

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	ד
/MC/	A2	WO 03/070304 A1	08-28-2003	G W Pharma Ltd.		
/MC/	А3	CA 2,129,594 A1	02-06-1996	Nacson et al.		
/1010/	A4	EP 0 459 677 A3	12-04-1991	Thermedics, Inc.		
/MC/	A5	WO 02/094234 A1	11-28-2002	Alexza Molecular Delivery		Г
/MC/	A6	WO 02/32487 A1	04-25-2002	G W Pharma Ltd.		
/MC/	A7	WO 03/037306 A2	05-08-2003	G W Pharma Ltd.		

Examiner Signature	/Michael Collins/ (04/25/2007)	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor inust precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

THADENAN Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/563,566			
Filing Date	02/23/2006			
First Named Inventor	Brain A. Whittle			
Art Unit	1712			
Examiner Name				
Attorney Docket Number	187287/US (466600-15)			

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
		US-			
<del></del>		US-			
		US-			
		US-	1	**************************************	
		US-			
		US-			
		US-			
		US-	<del>                                     </del>		
	-	US-			· · · · · · · · · · · · · · · · · · ·
		US-		W	
		US-	<del>                                     </del>		
		US-	1		<u> </u>
		US-	<del>                                     </del>		

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Τ	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵	
/MC/	A8	EP 0 672 416 A	09-20-1995	Euro Celtique SA			
<u> </u>				<u> </u>		L	
						L	
			ļ		İ	l	

Examiner Signature /Michael Collins/ (04/25/2007)

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
betwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known **Application Number** 1/563,566 INFORMATION DISCLOSURE Filing Date 02/23/2006 STATEMENT BY APPLICANT **First Named Inventor** Brain A. Whittle Art Unit 1712 (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet ĺЗ 3 . 187287/US/DJB/VEJ (466600-15)

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MC/	B1	HENDRIKS ET AL., Heroin Self-Admin. by 'Chasing the Dragon': Pharmacodynamics & Bioavail. of Inhaled Heroin, European Neuropsychopharm., April 4, 2001, pg.241-252, vol.11	
/MC/	B2	LICHTMAN ET AL., Inhalation Exposure to Volatized Opioids Produces Antinociception in Mice, J. of Pharm. and Exp. Therapeutics, June 5, 1995, pg.69-76, Vol.279, No.1	
		·	
	·	·	
		·	

Examiner Signature /Michael Collins/ (04/25/2007)	Date Considered	
---	--------------------	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1:98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.